Immune checkpoint blockers, such as CTLA-4 and PD-1/PD-L1 inhibitors, promote the development of tumor immunological responses for LGG, strengthening the unique role of tumor immune system responses [9–11]. This evidence concerns the gene CTLA4 and neoplasm.